Founded in 1999 and listed on the Australian Securities Exchange in 2004, Cogstate (ASX.CGS) is a world-class neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare.
Cogstate's Board and management are committed to shareholder value
Meet the Cogstate Board of Directors who bring a wealth of knowledge and experience to our business
See our Annual and Half Year reports
View Cogstate's recent investor presentations
View our upcoming financial events
See information on Cogstate's shareholder services
Cogstate digital technology provides rapid, reliable, and sensitive computerized assessment of cognition. For 20 years, the company has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world.
Cogstate’s easy-to-use, digital cognitive assessments are based on science which has been widely accepted and validated both academically and commercially through hundreds of peer-reviewed publications
Cogstate solutions serve four distinct markets: Clinical Trials, Healthcare, Academic Research and Brain Injury
Cogstate has a history of strong financial performance with the Clinical Trials business enabling the company to self-fund R&D and commercialisation opportunities
Cogstate leverages its leading expertise in cognitive testing to penetrate growing markets in Healthcare and Brain Injury
View Cogstate Limited’s share price and read our investor announcements on the Australian Securities Exchange.
Please fill out the form to subscribe